obesity

UK's private obesity drug market chooses Lilly's Mounjaro over Wegovy
Yahoo/Reuters
Fri, 12/13/24 - 11:43 am
Eli Lilly
Mounjaro
Novo Nordisk
Wegovy
UK
obesity
BioAge shares tumble after decision to halt obesity drug study
BioPharma Dive
Sun, 12/8/24 - 09:46 pm
BioAge
obesity
azelaprag
tirzepatide
clinical trials
Antag, a startup backed by Versant and Novo, joins hunt for obesity drug alternatives
BioPharma Dive
Wed, 12/4/24 - 11:15 pm
Antag Therapeutics
Versant
Novo Nordisk
obesity
For first phase of Mounjaro's obesity rollout in England, only a limited number of patients will have access
Fierce Pharma
Wed, 12/4/24 - 11:05 pm
Eli Lilly
Mounjaro
obesity
England
Lilly’s Zepbound beats Novo’s Wegovy in high-stakes obesity drug trial
BioPharma Dive
Wed, 12/4/24 - 11:02 am
Eli Lilly
Zepbound
Novo Nordisk
Wegovy
clinical trials
weight loss
obesity
Arrowhead seeks approval to begin RNAi therapy trial for obesity treatment
Clinical Trials Arena
Wed, 12/4/24 - 10:54 am
Arrowhead Pharmaceuticals
New Zealand
clinical trials
RNAi
ARO-ALK7
obesity
Health Canada approves Novo Nordisk's obesity drug to reduce risk of non-fatal heart attack
MSN
Wed, 11/27/24 - 09:57 pm
Novo Nordisk
Wegovy
Canada
Health Canada
obesity
Biden administration pushes anti-obesity drug pressure to Trump
Axios
Wed, 11/27/24 - 11:33 am
Joe Biden
Donald Trump
obesity
Medicare
Amgen says obesity drug caused up to 20% weight loss after a year, but shares drop 10%
CNBC
Tue, 11/26/24 - 11:08 am
Amgen
MariTide
obesity
Biden proposes Medicare and Medicaid cover weight loss drugs
Axios
Tue, 11/26/24 - 09:51 am
Joe Biden
Medicare
Medicaid
obesity
Novo Nordisk
Eli Lilly
Zepbound
Wegovy
Ozempic
Biohaven fails phase 3 SMA test but plans talks with FDA, plots move into obesity
Fierce Biotech
Mon, 11/25/24 - 11:22 am
Biohaven
taldefgrobep alfa
SMA
spinal muscular atrophy
FDA
obesity
Novartis: launch of Morphosys drug by could be 2027 or later
Pharma Live
Thu, 11/21/24 - 11:43 am
Novartis
pelabresib
MorphoSys
obesity
Versant startup sets out to make a new type of obesity drug
BioPharma Dive
Thu, 11/21/24 - 11:13 am
Pep2Tango
Versant Ventures
obesity
drug development
Weight-loss drug coverage rises among largest US employers, Mercer survey finds
MSN/Reuters
Wed, 11/20/24 - 11:30 am
employers
coverage
insurance
weight loss
obesity
Pfizer, Flagship return to obesity as part of latest additions to multibillion-dollar collaboration
Fierce Biotech
Wed, 11/20/24 - 11:22 am
Pfizer
Flagship Pioneering
obesity
drug development
Drugmakers and pharmacists battle over who gets to make obesity drugs
NPR
Wed, 11/20/24 - 11:21 am
Novo Nordisk
Eli Lilly
obesity
weight loss
GLP-1 agonists
compounded drugs
Eisai sunsets development, access program for withdrawn obesity med in Dravet syndrome
Fierce Pharma
Mon, 11/18/24 - 06:36 pm
Eisai
obesity
lorcaserin
Survey Finds Most GLP-1 Users Discontinue Drug Before Reaching Goal Weight
Xtalks
Fri, 11/15/24 - 11:27 am
Omada Health
GLP-1 agonists
obesity
weight loss
Novo Nordisk
Eli Lilly
Ozempic
Zepbound
Mounjaro
Wegovy
Amgen speaks out about bone density concerns with obesity drug
Clinical Trials Arena
Thu, 11/14/24 - 10:06 am
Amgen
obesity
bone density
MariTide
Gubra's weekly amylin obesity asset well-tolerated, tied to weight loss in phase 1 trial
Fierce Biotech
Wed, 11/13/24 - 09:46 pm
Gubra
obesity
GUBamy
clinical trials

Pages